EPISODE · Nov 30, 2023 · 6 MIN
A Cutting-Edge Cancer Treatment Is Under FDA Investigation—for Cancer Risk
from Science, Spoken · host WIRED
CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after approving the first treatment, the FDA is investigating whether it can give rise to secondary cancers. Read this story here. Learn more about your ad choices. Visit podcastchoices.com/adchoices
What this episode covers
CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after approving the first treatment, the FDA is investigating whether it can give rise to secondary cancers. Read this story here. Learn more about your ad choices. Visit podcastchoices.com/adchoices
NOW PLAYING
A Cutting-Edge Cancer Treatment Is Under FDA Investigation—for Cancer Risk
No transcript for this episode yet
Similar Episodes
No similar episodes found.